Leflunomide Ratiopharm (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug reduces the proliferation of activated lymphocytes, thereby decreasing the immune‑driven inflammation that characterises rheumatoid and psoriatic arthritis.

The dosage of Leflunomide Ratiopharm is determined by the prescribing physician based on the patient’s clinical condition, disease severity, and response to therapy. The prescriber will establish the appropriate dose and any necessary adjustments.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. It should not be used by breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both leflunomide and methotrexate are DMARDs used for rheumatoid arthritis, but they have different mechanisms. Leflunomide inhibits pyrimidine synthesis, while methotrexate interferes with folate metabolism. Choice between them depends on patient tolerance, liver function, and physician assessment of efficacy and safety.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in the bathroom or near heat sources, and keep out of reach of children.

Leflunomide Ratiopharm is taken orally as a tablet, usually with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe liver injury, aplastic anemia, pulmonary toxicity, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function, blood counts, and any signs of respiratory or dermatologic complications.

Leflunomide should not be used by pregnant women, women planning pregnancy, or those who are not using effective contraception. It is also contraindicated in patients with severe liver impairment, active infections, or known hypersensitivity to the drug.